WHAT IS CLAIMED IS:

1. An adenoviral vector including a DNA sequence encoding endostatin.

2. The vector of Claim 1 and further comprising a DNA sequence encoding a secretion signal peptide immediately 5' to said DNA sequence encoding endostatin.

3. The vector of Claim 2 wherein said secretion signal peptide is the secretion signal peptide of Ig-Kappa.

4. A method of providing for expression of endostatin in a host, comprising:

administering to a host the adenoviral vector of Claim 1.

5. The method of Claim 4 wherein said adenoviral vector is administered systemically.

6. The method of Claim 4 wherein said adenoviral vector is administered regionally.

7. The method of Claim 4 wherein the host is a mammalian host.

8. The method of Claim 7 wherein said adenoviral vector is administered in an amount effective to provide for expression of endostatin in an amount of up to 1,000,000 ng/ml.

9. The method of Claim 7 wherein said adenoviral vector is administered in an amount effective to provide for expression of said endostatin in said mammalian host in an amount of at least about 200 ng/ml.

10. The method of Claim 9 wherein said endostatin is expressed in said mammalian host in an amount of from about 200 ng/ml to about 500 ng/ml.

11. A method of treating a tumor in a host, comprising:

administering to said host the adenoviral vector of Claim 1.

12. The method of Claim 11 wherein said adenoviral vector is administered systemically.

13. The method of Claim 11 wherein said adenoviral vector is administered regionally.

14. A method of treating tumor metastases, comprising:

administering to a host the adenoviral vector of Claim 1.

15. The method of Claim 14 wherein said adenoviral vector is administered systemically.

16. The method of Claim 14 wherein said adenoviral vector is administered regionally.

17. The method of Claim 14 wherein said tumor metastasis is a tumor metastasis found in the liver.

18. The method of Claim 14 wherein said adenoviral vector is administered in an amount effecctive to provide for expression of endostatin in said host at a level of up to 1,000,000 ng/ml.

19. The method of Claim 14 wherein said adenoviral vector is administered in an amount effective provide for expression of endostatin in said host at a level of at least about 200 ng/ml.

20. The method of Claim 19 wherein said endostatin is expressed in said host at a level of from about 200 ng/ml to about 500 ng/ml.

21. A method of treating colon cancer metastases in a host, comprising:

administering to said host the adenoviral vector of Claim 1.

22. The method of Claim 21 wherein said adenoviral vector is administered systemically.

23. The method of Claim 21 wherein said adenoviral vector is administered regionally.

24. The method of Claim 21 wherein said colon cancer metastasis is a colon cancer metastasis found in the liver.

25. The method of Claim 21 wherein said adenoviral vector is administered in an amount effective to provide for expression of endostatin in said host at a level of up to 1,000,000 ng/ml.

26. The method of Claim 21 wherein said adenoviral vector is administered in an amount effective to provide for expression of said endostatin in said host in an amount of at least about 200 ng/ml.

27. The method of Claim 26 wherein said endostatin is expressed in said host in an amount of from about 200 ng/ml to about 500 ng/ml.

28. A method of expressing endostatin in a cell, comprising:

administering to a cell the adenoviral vector of Claim 1.

29. The method of Claim 28 wherein said cell is a mammalian cell.

30. The method of Claim 29 wherein said cell is an A549 cell.

31. The method of Claim 29 wherein said cell is a Hep3B cell.

add a'